In Brief: Former Bard execs sentencing
This article was originally published in The Gray Sheet
Former Bard execs sentencing: Judge Joseph Tauro, U.S. District Court, Boston, schedules Aug. 8 sentencing of three ex-Bard executives convicted in August 1995 of conspiring to defraud FDA ("The Gray Sheet" Aug. 28, 1995, p. 2). The former execs convicted are: Bard group exec VP David Prigmore; John Cvinar, former President of Bard's USCI angioplasty catheter division; and Lee Leichter, former director of regulatory affairs and quality assurance for USCI. Former Bard CEO, George Maloney, and Kenneth Thurston, former director of regulatory affairs for USCI, were acquitted. Charges facing Janice Piasecki, a former supervisor in the regulatory affairs department, were dropped. The three defendants found guilty each face up to five years imprisonment and a fine of $250,000...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.